Informationes plurimae ― Latine

Laser Q-switched Nd:YAG nevus de Ota et similibus conditionibus efficaciter tractare notus est. Studium perduximus videndi quam bene laser high-fluence 1064 nm Q-switched Nd:YAG in locis inusitatis Mongolicae laboravit, quin cutem levaret. Studebamus aegros 61 his epulis, examinando summam 70 laesiones. Dimidium laesiones cum laser tractatae sunt, aliae ad comparationem increatae relictae. Nos eventus aestimavimus utentes magnitudine et artificio Mexameter® vocatum ut gradus melaninarum metirentur. Aegros quattuor mensibus in curatione coetus et XVIII mensium in coetu observationis insecuti sunt. In fine studii notabiles differentias invenimus in gradibus ustulo et melanino inter circulos tractatos et increatos, cum coetus laser-tractatus meliores eventus ostendentes. Laser high-fluence Q-switched Nd:YAG , sine cutis levatione, efficax et tuta probata est ad has maculas Mongolicas insolitas tractandas.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.

Studebamus efficaciam et salutem utendi laser sionis specificae pro ABNOM , et spectavimus quid causae afficerent quam bene operaretur. Inspeximus 110 aegros qui ABNOM habebant et inter duas curationes laseris et novem comparavimus. Id curatio meliore facta diutius invenimus, sed non tam in vetustioribus aegris. Etiam melius in aegris cum levioribus cutibus laboravit (species III) et locis affectis minoribus (minus quam 10 cm2) . Cum melasma una cum ABNOM curationem minus efficacem fecit. Color vel numerus arearum affectarum differentiam facere non videtur. Circa 10% aegrorum post curationem maculas obscuriores obtinuit. Mane multa curatio bonos eventus dedit. Antiquiores aegris cum cutis obscuriore et obscuriore macula sunt, magis verisimile post curationem maculas obscuriores accipere. Aegris cum ABNOM et melasma, satius est laser energia inferiore uti ne melasma peius fiat.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.